APRE - Biotech Bid Up Following First Patient Dosage

A Boston-based %Biotech company is turning heads on Wednesday after the company announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations, according to the release.

Traders quickly jumped at this opportunity and are currently bidding shares of %ApreaTherapeutics () up at $0.48/share (+5.40% implied open for sellers) at the time of writing. This move could be a strong continuation of the rally that has occurred since the company made a new 52-week low of $0.304 to finish the year of 2022.

Aprea Therapeutics Inc is a clinical-stage %Biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).